Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
10. Dezember 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
04. Dezember 2024 16:30 ET
|
Cellectis Inc.
PARIS, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Monthly information on share capital and company voting rights
06. November 2024 16:38 ET
|
Cellectis Inc.
PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
05. November 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
04. November 2024 16:30 ET
|
Cellectis Inc.
UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in 2025AstraZeneca partnership: R&D activities are ongoing on three programs – one...
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
30. Oktober 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Monthly information on share capital and company voting rights
02. Oktober 2024 16:30 ET
|
Cellectis Inc.
PARIS, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Monthly information on share capital and company voting rights
04. September 2024 16:30 ET
|
Cellectis Inc.
PARIS, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
26. August 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
07. August 2024 02:00 ET
|
Cellectis Inc.
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...